痴呆与年龄相关性黄斑变性的共病提示需提高临床意识:一项荟萃分析
该荟萃分析检索1959年3月至2018年3月多个数据库,纳入21项研究共7,876,499名研究对象,评估痴呆/阿尔茨海默病(AD)与年龄相关性黄斑变性(AMD)的关联。结果显示痴呆或AD患者AMD风险升高,AMD也与AD/认知障碍风险增加相关,且AMD患者认知功能评分较对照更差。作者认为痴呆/AD与AMD存在显著关联,提示需提高临床意识。
要点
- 痴呆患者AMD风险升高(校正后p≤0.017,OR≥1.24,I²≤9%),尤其晚期AMD(校正后p<0.001,OR=1.37,I²=0)。
- AD患者AMD风险升高(p=0.001,未校正OR=2.22,I²=50%)。
- AMD与AD/认知障碍风险增加显著相关(校正后p=0.037,OR=2.42,I²=38%),AMD患者认知功能较对照更差。
核心结论
- 痴呆/AD与AMD之间存在显著关联,提示需提高临床意识。
- 对原发诊断为痴呆/AD或AMD的患者常规筛查另一疾病的成本效益需进一步研究。
研究设计与样本
- 荟萃分析检索MEDLINE、EMBASE、Web of Knowledge、PsycInfo和Cochrane系统评价数据库,纳入1959年3月至2018年3月发表的横断面、病例对照和队列研究。
- 共纳入21项研究,合计7,876,499名研究对象,采用随机效应模型估计汇总OR、相对风险、均数差及95%CI。
- 基于研究质量和单项研究效应进行敏感性分析,并以Egger检验评估偏倚。
主要发现
- 痴呆患者AMD风险升高(校正后p≤0.017,OR≥1.24,I²≤9%),AD患者AMD风险升高(p=0.001,未校正OR=2.22,I²=50%)。
- 痴呆患者晚期AMD风险升高(校正后p<0.001,OR=1.37,I²=0)。
- AMD与AD/认知障碍风险增加显著相关(校正后p=0.037,OR=2.42,I²=38%)。
- AMD患者简易精神状态检查评分较对照更差(p<0.001,I²≤79%),连线测试A部分亦更差(p<0.001,I²=0)。
- 敏感性分析和Egger检验提示结果较少可能受偏倚影响。
临床怎么用
- 作者认为痴呆/AD与AMD的显著关联提示需提高临床意识。
- 作者指出对原发诊断为痴呆/AD或AMD的患者常规筛查另一疾病的成本效益需进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To determine the association between dementia and age-related macular degeneration (AMD) using meta-analysis. METHODS: We searched in the MEDLINE, EMBASE, Web of Knowledge, PsycInfo and Cochrane database of systematic reviews for studies published from March 1959 to March 2018. We included cross-sectional, case-control and cohort studies that evaluated the association of dementia/Alzheimer's disease (AD) with AMD (as outcome) and the association of AMD with dementia/AD (as outcome). Studies that compared cognitive functions between AMD and controls were also included. The summary outcomes, namely odds ratio (OR), relative risk, mean differences and corresponding 95% CIs, were estimated using random effects models. We performed sensitivity analysis based on study quality and individual study effect to control for potential biases. RESULTS: Among 2159 citation records, we identified 21 studies consisting of 7 876 499 study subjects for meta-analysis. Patients with dementia (padjusted≤0.017, OR≥1.24, I2≤9%) or AD (p=0.001, ORunadjusted=2.22, I2=50%) were at risk for AMD, particularly for late AMD (padjusted<0.001, OR=1.37, I2=0). AMD was also significantly associated with increased risk of AD/cognitive impairment (padjusted=0.037, OR=2.42, I2=38%). Moreover, patients with AMD had poorer cognitive functions when compared with controls, including Mini-Mental State Examination (p<0.001, I2≤79%) and Trail Making Test A (p<0.001, I2=0). Sensitivity analysis and Egger's test indicated our results were less likely biased. CONCLUSIONS: A significant association between dementia/AD and AMD calls for greater clinical awareness. The cost-effectiveness of routine screening for the other condition in patients with primary diagnosis of dementia/AD or AMD requires further study.
引用
- Rong SS, Lee BY, Kuk AK, et al. Comorbidity of dementia and age-related macular degeneration calls for clinical awareness: a meta-analysis. Br J Ophthalmol. 2019. PMID: 31000510. doi:10.1136/bjophthalmol-2018-313277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。